Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: Correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation
L. Di Marzio et al., Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: Correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation, CLIN IMMUNO, 92(1), 1999, pp. 103-110
The aim of this study was to investigate the impact of long-term acetyl-L-c
arnitine administration on CD4 and CD8 absolute counts, apoptosis, and insu
lin-like growth factor-1 (IGF-1) serum levels in HIV-1-infected subjects. T
he generation of cell-associated ceramide and HIV-1 viremia were also inves
tigated. Eleven asymptomatic, HIV-1-infected subjects were treated daily wi
th acetyl-L-carnitine (3 g) for 5 months. Immunologic and virologic measure
s and safety were monitored at the start of the treatment and then on days
90 and 150. Altogether our findings suggest that acetyl-L-carnitine adminis
tration has a substantial impact on the main immunologic abnormality associ
ated with HIV infection, the loss of CD4 cells, by reducing the rate of apo
ptotic lymphocyte death. The reduction of cel-amide generation anti the inc
rease of the serum levels of IGF-1, a major survival factor able to protect
cells from apoptosis by different stimuli and conditions, could represent
two important mechanisms underlying the observed anti-apoptotic effects of
acetyl-L-carnitine. (C) 1999 Academic Press.